Eruptive basal cell carcinoma and lenalidomide: rising awareness among dermatologists.
Basal Cell
Carcinoma
Chemoprevention
Lenalidomide
Skin Neoplasm
Journal
Dermatology reports
ISSN: 2036-7392
Titre abrégé: Dermatol Reports
Pays: Italy
ID NLM: 101566470
Informations de publication
Date de publication:
07 Mar 2023
07 Mar 2023
Historique:
received:
25
05
2022
accepted:
04
07
2022
medline:
18
4
2023
entrez:
17
4
2023
pubmed:
18
4
2023
Statut:
epublish
Résumé
Because of its higher level of safety compared to its parent medicine, thalidomide, lenalidomide (L) is chosen for the treatment of multiple myeloma. We report a patient who, within a month of using L, developed more than 10 basal cell carcinomas.
Identifiants
pubmed: 37063400
doi: 10.4081/dr.2022.9534
pmc: PMC10099294
doi:
Types de publication
Journal Article
Langues
eng
Pagination
9534Informations de copyright
©Copyright: the Author(s).
Déclaration de conflit d'intérêts
Conflict of interest: The authors declare no potential conflict of interest.
Références
Blood. 2012 Mar 22;119(12):2764-7
pubmed: 22323483
N Engl J Med. 2015 Oct 22;373(17):1618-26
pubmed: 26488693
J Am Acad Dermatol. 2004 Aug;51(2):293-300
pubmed: 15280852
Ther Adv Hematol. 2016 Aug;7(4):209-21
pubmed: 27493711
J Am Acad Dermatol. 2016 Jul;75(1):210-2
pubmed: 27317516